|
表观遗传学(epigenetics)是不改变DNA碱基序列,却能引发可遗传基因表达改变的调控方式,主要包括DNA甲基化、组蛋白修饰与非编码RNA调控三类机制。其中组蛋白修饰是在相关酶的催化下,发生甲基化、乙酰化、磷酸化、泛素化等共价修饰的生物学过程。组蛋白修饰通过改变组蛋白与双链DNA的结合亲和力,调控染色质呈松散或凝集状态,同时还可影响转录因子与结构基因启动子的结合能力,进而实现基因表达调控。依托组蛋白修饰可逆特性,HDAC、EZH2等靶向抑制剂已批准上市,成为表观靶向药物研发的重要方向。[1-3]
图1. 组蛋白甲基转移酶(HMTs)和组蛋白去甲基化酶(HDMs)对自噬的表观调控[4] 靶向调控组蛋白甲基化修饰小分子:
图2. 组蛋白乙酰转移酶(HATs)与组蛋白去乙酰化酶(HDACs)对自噬的表观调控[4] 靶向调控组蛋白乙酰化修饰小分子:
参考文献: [1] Shi Yuncong, et al. Epigenetic Regulation in Cardiovascular Disease: Mechanisms and Advances in Clinical Trials. Signal Transduction and Targeted Therapy, vol. 7, no. 1, 25 June 2022, p. 200. [2] Dai Wanlin, et al. Epigenetics-targeted drugs: current paradigms and future challenges. Signal Transduction and Targeted Therapy, vol. 9, 2024, p. 332. [3] Elizabeth A. Heller, et al. Epigenetic editing: from concept to clinic. Nature Reviews Drug Discovery, vol. 25, 2026, pp. 227–248. [4] Seo Jieun, et al. Transcriptional and Epigenetic Regulation of Autophagy: Mechanisms, Disease Relevance and Therapeutic Opportunities. Signal Transduction and Targeted Therapy, vol. 11, 2026, p216.
|
相关产品
- GSK2879552
- Butyrolactone 3
- MR837
- MS023
- Birabresib (OTX015)
- Pemrametostat (GSK3326595)
- OSS_128167
- OICR-9429
- NSC 663284
- QC6352
- GSK-J4
- ICG-001
- BIX-01294
- IOX1
- RGFP966
- CPI-455
- A-485
- Pinometostat (EPZ-5676)
- Anacardic acid
- Romidepsin
- Trichostatin A (TSA)
- Entinostat (MS-275)
- Nicotinamide (Vitamin B3)
- GSK126
- Selisistat (EX 527)
- Tazemetostat (EPZ-6438)
- (+)-JQ1
- Vorinostat (SAHA)





鲁公网安备37011202002432号